Research & Development: Page 4
-
Stock via Getty Images
In a Duchenne market beset by problems, Capricor data marks a bright spot
The company’s cell therapy recently showed positive results from a mid-stage trial.
By Kelly Bilodeau • Aug. 5, 2024 -
Stock via Getty Images
OpinionWhat pharma has learned from AI
As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.
By Meagan Parrish • Aug. 2, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Drew Angerer via Getty Images
Pfizer’s Bourla confident in company’s obesity drug position, despite delays
The CEO noted how Pfizer's danuglipron could still be the second oral GLP-1 treatment to enter registrational tests after Lilly's orforglipron.
By Jonathan Gardner • Aug. 1, 2024 -
Permission granted by Sanofi
7 years after launch, Sanofi’s Dupixent is set for a megablockbuster run
Dupixent hasn’t generated as much buzz as top-sellers like Keytruda or Ozempic, but the drug is boosting Sanofi’s earnings into the future.
By Michael Gibney • July 30, 2024 -
Stock via Getty Images
Neuro drugs are still faltering, despite rising investment
A brain-on-a-chip developer says better preclinical modeling could help move the needle.
By Kelly Bilodeau • July 29, 2024 -
Permission granted by Biogen
Sage’s recent trial failure adds pressure to its two-drug Biogen collab
The mid-stage failure leaves the success of the expensive partnership hanging on a drug that’s already suffered its own setback.
By Amy Baxter • July 29, 2024 -
Stock via Getty Images
Citius’ first FDA decision date is approaching — and its CEO has millions on the line
Citius Pharmaceuticals CEO Leonard Mazur has personally invested $22.5 million into the company, which is fast approaching a potential turning point.
By Amy Baxter • July 26, 2024 -
Permission granted by Mubadala Capital
Q&AIn biotech’s new market normal, here’s what’s catching this investor’s eye
A VC investor shares how the market is recovering, which kinds of companies he’s hunting for and where he’d love to see more innovation.
By Meagan Parrish • July 25, 2024 -
Brian Tucker / BioPharma Dive
Private biotech M&A surges amid difficult IPO market
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
By Gwendolyn Wu • July 23, 2024 -
Alex Wong / Staff via Getty Images
Q&ABird flu puts BARDA back in the spotlight
BARDA director Gary Disbrow explains the agency’s focus, how companies can get their “foot in the door” and why platforms are so important for preparedness.
By Alexandra Pecci • July 23, 2024 -
Stock via Getty Images
To overcome barriers, cell and gene therapies need outside support
With great potential in cell and gene therapies, there are still plenty of barriers to getting the breakthroughs to patients.
By Kelly Bilodeau • July 22, 2024 -
Stock via Getty Images
Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder
The pharma company is tackling the “stiff person syndrome” that afflicts Celine Dion in a phase 2 trial for its lead CAR-T candidate.
By Amy Baxter • July 19, 2024 -
Justin Sullivan via Getty Images
Gilead’s CMO to depart next year
Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.
By Ned Pagliarulo • July 19, 2024 -
Permission granted by Gilead
Gilead eyes ‘ending the HIV epidemic’ via incremental progress
With a long elusive HIV cure ever on the horizon, Gilead’s latest long-acting PrEP study shows that every step counts.
By Michael Gibney • July 18, 2024 -
Permission granted by Amylyx
Q&AAmylyx’s CEOs on their ALS setback and quest to revamp the pipeline
Co-CEOs Josh Cohen and Justin Klee reflect on what they learned from Relyvrio’s failure and how they’re carrying those lessons forward with other drugs.
By Meagan Parrish • July 17, 2024 -
Doucefleur via Getty Images
Biotech SpotlightA new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill
Ensho Therapeutics just launched but is already generating buzz with its phase 2-ready clinical program for inflammatory bowel disease.
By Alexandra Pecci • July 17, 2024 -
Getty Images via Getty Images
Has pharma emerged from the ‘age of uncertainty’?
An industry reeling from a precarious market is showing signs of stabilizing as the future becomes a little less cloudy, an Evaluate report suggests.
By Michael Gibney • July 16, 2024 -
Stock via Getty Images
Is a better CAR-T cell therapy option on the horizon?
In vivo CAR-T cell technology has the potential to solve some major issues in the field and could enter the clinic this year.
By Kelly Bilodeau • July 15, 2024 -
Stock via Getty Images
Biotech SpotlightMining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders
Mid-stage data from the company’s lead candidate in Parkinson’s is expected later this year and could tee up an IPO.
By Meagan Parrish • July 15, 2024 -
Courtesy of BMS
BMS’ long-standing leukemia blockbuster stares down its first generic
Patent disputes in the U.S. and abroad have opened the door to new generics ready for launch as soon as September for BMS’ Sprycel.
By Amy Baxter • July 12, 2024 -
Jeenah Moon via Getty Images
Pfizer research chief Dolsten to step down, with company at a crossroads
The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals alongside notable setbacks during his time as Pfizer’s top scientist.
By Ben Fidler • July 10, 2024 -
Stock via Getty Images
Could pharma’s blockbuster immunotherapies work in dogs?
Vetigenics believes it’s found a way to make pricey antibody-based technologies more accessible for animals.
By Alexandra Pecci • July 9, 2024 -
Getty Images via Getty Images
The FDA pushes concrete plans to further diversity in clinical trials
The long-awaited guidance offers a more detailed road map for pharma.
By Kelly Bilodeau • July 8, 2024 -
Permission granted by GeoVax
In the rapidly shrinking COVID market, this company still sees opportunity
GeoVax is developing a next-gen COVID vaccine targeting a population that’s so far been elusive: immunocompromised patients.
By Alexandra Pecci • July 3, 2024 -
Permission granted by BeiGene
Q&AHow BeiGene is taking on established blockbusters with an expanding blood cancer arsenal
BeiGene’s Brukinsa is the first in a hematology franchise that the company hopes will rival top-sellers and introduce a new lineup of medicines for patients.
By Michael Gibney • July 2, 2024
Previous
